Aspen’s International business comprises operating subsidiaries in Europe CIS, Latin America, Middle East and North Africa ("MENA"), Canada as well as Mauritian-based AGI, the international commercial business and intellectual property holding company which is also a primary Group trading operation and supply chain hub. Globally branded pharmaceutical products are distributed into multiple territories as well as local brands into selected regions. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville site primarily services Group supply needs and the Bad Oldesloe site is also an important producer for the Group.


Europe CSI

Key business units

Aspen Bad Oldesloe
Aspen Europe
Aspen France
Aspen Germany
Aspen Ireland
Aspen Italy

Aspen Netherlands
Aspen Oss
Aspen Polska
Apsen Russia
Aspen Switzerland

Latin America

Key business units

Aspen Argentina
Aspen Brazil
Aspen Caricam
Aspen Chile
Aspen Colombia
Aspen Ecuador

Aspen Mexico
Aspen Panama
Aspen Peru

Rest of the World

Key business units

Aspen API
Aspen Canada
Aspen Dubai

Key territories and/or countries supplied to in this region

Argentina • Brazil • Canada • Caricam • Chile • CIS • Colombia • Ecuador
• Europe • Mexico • MENA • Panama • Peru • USA

• Aspen’s International business contributed 49% towards total Group comparable gross revenue in the 2016 financial year, with the Europe CIS business contributing 36% of total Group gross revenue.

• Mono-Embolex, an injectable and weight independent anticoagulant, acquired from Novartis in the prior financial year, has been successfully integrated in Germany and posted its first full year of sales in the 2016 financial year. Mono-Embolex presents a strong complementary fit to Aspen’s thrombosis portfolio and is now promoted as a first-line product to key stakeholders.

• In a transaction which became effective on 1 October 2016, Aspen acquired the exclusive rights to commercialise AstraZeneca’s global (excluding the USA) anaesthetics portfolio for a consideration of USD520 million in June 2016. The products in the portfolio are sold in more than 100 countries worldwide including China, Japan, Australia and Brazil and generated revenue of USD592 million in the year ended 31 December 2015.

• The acquisition of a global portfolio (excluding North America) of GSK anaesthetic products for a consideration of GBP180 million was announced by Aspen after its year end close. These products are sold in more than 100 countries worldwide including China, Japan, Brazil, Korea, Germany and Italy.

• In the Caribbean and Central America ("Caricam") territory, third-party distributors were replaced by Aspen’s own operations, thereby reducing complexity in the supply chain.

• The Vallejo site received the "Environmental Excellence Recognition Award" for the second year in a row for demonstrating continuous improvement in production processes, clean and effective sustainable practices and its community commitment.

• In December 2015, AGI acquired the intellectual property and the approved ANDA in the USA in respect of the FDF of HPC, which is indicated for the treatment of certain female cancers and hormonal imbalances. It was officially launched on 28 June 2016 in the USA.

• The European and CIS thrombosis pharmaceutical market was valued at
EUR2,7 billion, growing 1,2% in volume and declining marginally by 0,3% in value, for the year to 30 June 2016.

• Aspen is the second largest manufacturer of injectable anticoagulants in Europe CIS and is the sector leader for these products in Bulgaria, Czech Republic, the Netherlands and Romania.

• The Spanish Latin American private pharmaceutical sector was valued by IMS at USD32,1 billion for the year to 30 June 2016.

• The Brazilian private pharmaceutical sector was valued by IMS at USD22,5 billion for the year to 30 June 2016 and Aspen is ranked 53rd in this sector.

• The MENA pharmaceutical sector was estimated at approximately USD28,5 billion for the year to 31 December 2015.

• Aspen’s major markets in the MENA region include Saudi Arabia, Egypt, Algeria, Kuwait and Morocco.

Contribution to Group
comparable gross revenue

Contribution to Group
comparable EBITA

Number of products launched from pipeline:

Europe CIS:
(2015: Nil)
Latin America:
(2015: 43)
Rest of the World:
(2015: Nil)

IMS value of pipeline as at 30 June 2016 anticipated to be launched in:

0 – 2 years
USD0,85 billion
3 – 5 years
USD2,20 billion​​​​​​​

Number of permanent employees:

Europe CIS:
2 611 (2015: 2 608)
Latin America:
1 245 (2015: 1 360)
Rest of the World:
247 (2015: 235)

Average staff turnover:

Europe CIS:
8% (2015: 5%)
Latin America:
33% (2015: 33%)
Rest of the World:
20% (2015: 17%)

Number of product recalls:

6 (2015: 1)​​​​​​​

Number of work-related fatalities:

Nil (2015: Nil)

Carbon emissions:

Scope 1:
32 415 tCO2e
(2015: 34 858 tCO2e)
Scope 2:
32 744 tCO2e
(2015: 31 340 tCO2e)